Le Lézard
Classified in: Ebola virus, Health
Subject: SVY

Global Emerging Infectious Diseases Vaccine Markets 2018-2019: Focus on Ebola Vaccine Pipeline, Zika Vaccine Pipeline & MERS-CoV Vaccine Pipeline


DUBLIN, Jan. 11, 2019 /PRNewswire/ --

The "Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

"Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies" finds that philanthropic organizations and public-private partnerships like the Coalition for Epidemic Preparedness Innovations (CEPI) are filling a niche for funding translational and clinical vaccine research, allowing development of vaccines for diseases such as Lassa fever to occur even in the absence of an ongoing epidemic. As of November 2018, there were 235 vaccines in preclinical investigation, clinical development, or marketed for twelve major EIDs.

Although development of interventions for emerging infectious diseases (EIDs) has traditionally been limited by a lack of market incentives, novel funding mechanisms and global partnerships for outbreak preparedness are expanding the commercial prospects for vaccine developers.

EIDs are uniquely challenging for vaccine development due to unpredictable clinical incidence or geographical patterns. In response to recent global outbreaks, such as the 2013-2016 West African Ebola epidemic, global partnerships have been formed to stimulate vaccine development with a blend of push and pull market incentives. Chief among these are advanced market commitments (AMCs) from health organizations to subsidize vaccine development by purchasing a vaccine before licensure.

The report also finds that 90.2% of marketed or experimental vaccines for major EIDs are still in preclinical or clinical development, leaving significant opportunity for drug developers to enter relatively open disease landscapes for numerous indications.

There is a wide gap in the stage of vaccine development for different EIDs. For instance, there have been 57 planned, ongoing, or completed clinical trials for vaccines to prevent Ebola virus disease, and Merck's Phase III product, V920, is expected to receive FDA approval in 2019. However, the majority of EIDs do not have any licensed vaccine products. Some EIDs including Middle East Respiratory Syndrome (MERS) and Crimean-Congo Hemorrhagic Fever (CCHF) have had experimental vaccines tested in fewer than six clinical trials. Adaptive clinical trial design will play a major role in the pivotal studies of pipeline vaccines for EIDs.

KOLs believe that regulators and vaccine developers are moving towards adaptive clinical trials that factor in rapid surges and declines in disease incidence. Instead of requiring a single large, randomized Phase III trial for vaccine approval, new strategies include collecting and combining data across multiple outbreaks, and expanding avenues for post-marketing studies to evaluate safety and clinical benefit.

Major EIDs include Zika, Ebola, MERS, Lassa, Marburg, Severe Acute Respiratory Syndrome (SARS), Chikungunya, CCHF, West Nile, Dengue, Yellow Fever, H5N1.

This report covers current and future challenges for the development and deployment of vaccines for EIDs, focusing on vaccine platform technology and research, funding mechanisms, and collaborative global partnerships.

Scope

Key Topics Covered:

1. Preface
1.1 1.2 Abbreviations
1.3 Related Reports
1.4 Upcoming Related Reports

2. Executive Summary
2.1 Key Findings
2.2 KOL Insights on Vaccines for Emerging Infectious Diseases

3. Overview of Emerging Infectious Diseases
3.1 Defining Emerging Infectious Diseases (EIDs)
3.2 Drivers of Emerging Infections & Routes of Transmission
3.3 Key EIDs
3.4 Ebola Virus Disease
3.5 Zika Virus Disease
3.6 Middle East Respiratory Syndrome (MERS) and Other EIDs

4. Clinical Trial Design
4.1 Clinical Trial Design Challenges
4.2 Randomization Units
4.3 Selection of Clinical Trial Population and Comparator
4.4 Additional Strategies for Vaccine Approvals
4.5 Unmet Needs in Clinical Trial Design

5. Vaccine Platform Technologies
5.1 Overview of Vaccine Platform Technologies
5.2 Vaccine Platforms By Stage of Development
5.3 Live-attenuated Vaccines
5.4 Viral Vector-Based Vaccines
5.5 DNA Vaccines
5.6 Whole-Inactivated Vaccines, Subunit Vaccines, and VLPs

6. Funding and Market Incentives
6.1 Funding Sources for Vaccines for EIDs
6.2 Push and Pull Incentives
6.3 Challenges for Funding of Vaccine Development
6.4 Lessons from the Ebola and Zika Outbreaks

7. Global Collaborations for Vaccine Development
7.1 Global Vaccine Development Fund and Priority Diseases
7.2 Coalition for Epidemic Preparedness Innovations (CEPI)
7.3 Vaccine Preparedness
7.4 Global Virome Project (GVP) and Other Public-Private Partnerships

8. Pipeline Vaccines for Key Emerging Infectious Diseases
8.1 Clinical Development of Vaccines for EIDs
8.2 Ebola Vaccine Pipeline
8.3 Zika Vaccine Pipeline
8.4 MERS-CoV Vaccine Pipeline

9. Surveillance and Healthcare Infrastructures
9.1 Disease Surveillance for EIDs
9.2 Logistical Challenges for Vaccine Delivery
9.3 Vaccine Preparedness
9.4 Unmet Needs in Basic Vaccine Research

10. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/gxtfsr/global_emerging?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

16 jan 2019
Mirati Therapeutics, Inc. today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are expected to be...

16 jan 2019
PharmaCielo Ltd. (the "Company" or "PharmaCielo"), formerly AAJ Capital 1 Corp. ("AAJ") is pleased to announce that effective January 15, 2019, it completed its previously announced qualifying transaction (the "Qualifying Transaction") pursuant to...

16 jan 2019
ENCINO, Calif., Jan. 16, 2019 /PRNewswire-PRWeb/ -- Parents and children alike are learning skills for anxiety relief, and other tools for mental wellness, from a new podcast. Dear Anxiety, a production of GoZen!, premiered in January 2019 and made...

16 jan 2019
This report analyzes the worldwide markets for Prepackaged Medical Kits and Trays in US$ Thousand by the following Product Segments: ENT Custom Trays, Ophthalmic Custom Trays, Custom Basin Kits, Custom Ob/Gyn Kits, General Delivery Kits, Hysterectomy...

16 jan 2019
KEY FINDINGSThe global small cell market is forecasted to rise at a CAGR of 25.16% for the period 2019-2027, generating $XX million revenue at the end of 2027. The market is mainly driven by factors such as the growing propagation of small cells,...

16 jan 2019
This report analyzes the worldwide markets for Intraocular Lenses in US$ Thousand and Thousand Units by the following Segments: Standard Intraocular Lenses, and Premium Intraocular Lenses.Read the full report: https://www.reportlinker.com/p05205331...



News published on 11 january 2019 at 09:00 and distributed by: